MASS stock forecast, quote, news & analysis
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis... Show more
908 Devices (MASS) Stock Analysis: Handheld Chemical Detection Leader Consolidates After a Strong 2026 Rally
Key Takeaways
- 908 Devices (MASS) trades near $11.53 as of the latest session, down roughly 6.6% from its September 30 closing level of $12.34 over the trailing 30 days.
- The stock reached a 52-week high of about $13.35 in early October before consolidating, reflecting a pullback after a multi-month advance.
- Second-quarter 2026 revenue rose 23% year over year to $16.1 million, and management raised full-year 2026 revenue guidance to a range of $68 million to $70 million.
- The company operates with a debt-free balance sheet and held roughly $101.5 million in cash and marketable securities at the end of the second quarter.
- Analyst consensus on the stock is "Strong Buy," with an average 12-month price target near $13.38, according to recent market data.
- The company's next earnings report is scheduled for November 10, 2026, a key event for near-term sentiment.
- For additional detail on valuation, fundamentals, and expectations, explore 908 Devices' Price Targets, Earnings, and Forecast pages.
- Traders and investors seeking automated strategies can browse Tickeron's Trending AI Robots.
Current Market Snapshot
908 Devices Inc. has been one of the stronger performers among small-cap technology and defense-adjacent names in 2026. After trading in a range around $7 to $8 earlier in the year, the stock climbed steadily through the summer and autumn, reaching a 52-week high near $13.35 in early October before giving back some ground. The latest available price of roughly $11.53 represents a decline of about 6.6% from the $12.34 close recorded 30 days earlier, though the stock remains well above its 52-week low of $5.03.
Market sentiment around the name has been supported by accelerating revenue growth, an improving profitability trajectory, and durable demand tailwinds tied to the opioid crisis, defense modernization, and border-security spending. At the same time, the recent consolidation suggests investors are pausing to assess valuation and the pace of the company's push toward sustained profitability.
908 Devices (MASS) Business Overview and Competitive Position
Headquartered in Burlington, Massachusetts, and founded in 2012, 908 Devices develops purpose-built, handheld instruments for point-of-need chemical analysis. The company combines high-pressure mass spectrometry, optical spectroscopy, and machine learning to shrink capabilities once confined to laboratory instruments into battery-powered, field-deployable devices.
Its flagship product, the MX908, is a handheld mass spectrometer used for trace detection of drugs, explosives, and chemical hazards. The broader portfolio includes FTIR-based devices such as the VipIR, XplorIR, ThreatID, and ProtectIR, which identify unknown gases, vapors, and solids, as well as the NIRLab near-infrared drug-screening platform acquired in May 2026. The company serves law enforcement, first responders, defense, and federal agencies globally.
A defining competitive strength is the lack of direct handheld mass-spec rivals, alongside an installed base of more than 4,100 devices. Recurring revenue from software subscriptions and connected services is a growing part of the model, providing a path toward higher-margin, predictable revenue.
Recent Developments Driving MASS
The most significant recent catalyst was the company's second-quarter 2026 results, which showed 23% year-over-year revenue growth to $16.1 million and a more than 50% improvement in adjusted EBITDA losses. Management raised full-year 2026 revenue guidance to $68 million to $70 million, implying growth of roughly 21% to 25%. The quarter also highlighted momentum in the VipIR FTIR device and early traction for the NIRLab acquisition.
Analyst activity has been supportive. Following the second-quarter beat, several firms raised price targets, and Canaccord initiated coverage with a Buy rating and a $13.50 target. The consensus rating stands at "Strong Buy." These developments contributed to the stock's climb toward its 52-week high in early October. The subsequent pullback appears to reflect broader profit-taking and positioning ahead of the company's third-quarter report scheduled for November 10, 2026, rather than any change in the underlying business narrative.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a broader platform offering hundreds of automated strategies across thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving users a focused view of strategies that have recently demonstrated strength. These bots vary widely in approach, timeframe, and performance metrics, allowing traders to evaluate options that align with their own goals and risk tolerance. Investors interested in systematic, data-driven approaches to the market can explore the page to review current top performers.
2026 Outlook and What Investors Should Watch
Looking ahead, the company's November 10 earnings release will be the primary near-term catalyst, with investors focused on whether momentum in handheld device placements continues and whether adjusted EBITDA losses keep narrowing. Management has signaled recurring revenue could trend toward 40% of total revenue over time, driven by NIRLab subscriptions and connected services, and progress on that metric will be closely watched.
Demand drivers remain constructive, including federal grant funding flows to state and local agencies, defense budget growth, and the continued need to modernize chemical detection equipment. Key risks include the uncertain status of certain military programs, execution on the NIRLab integration, and the challenge of sustaining growth while still reporting net losses. As with any small-cap growth company, valuation sensitivity and broader market conditions may influence share-price volatility in the months ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MASS sees MACD Histogram just turned negative
MASS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 46 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for MASS moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MASS as a result. In 79 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MASS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MASS entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
MASS moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +13.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where MASS advanced for three days, in 225 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
MASS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.443) is normal, around the industry mean (4.142). P/E Ratio (-11.116) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (5.988) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. MASS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MASS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices